Replication Repair Deficient
2 clinical trials · Condition
◉ Watch Replication Repair Deficient
| Record | Firm | Date |
|---|---|---|
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG (NCT07644312) | Nationwide Children's Hospital | 2027-03-01 |
| A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) (NCT06519682) | Daniel Morgenstern | 2024-12-06 |
Track Replication Repair Deficient automatically
Every clearance here is in the API, with alerts when new ones post.